AR117963A2 - Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina - Google Patents
Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilaminaInfo
- Publication number
- AR117963A2 AR117963A2 ARP200100066A ARP200100066A AR117963A2 AR 117963 A2 AR117963 A2 AR 117963A2 AR P200100066 A ARP200100066 A AR P200100066A AR P200100066 A ARP200100066 A AR P200100066A AR 117963 A2 AR117963 A2 AR 117963A2
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- chiral auxiliary
- alkyl
- nucleophile
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un proceso para la preparación de un compuesto de fórmula (1) o una sal, hidrato, solvato o polimorfo farmacéuticamente aceptable de éste, en donde: R¹ es -CH₃; y cada uno de R², R³, R⁴, R⁵ y R⁶ es en cada aparición independientemente hidrógeno, halo, alquilC₁₋₆, alcoxiC₁₋₆, -CF₃, -CN o -NO₂, caracterizado porque comprende: (a) la condensación de un auxiliar quiral con un aldehído que tiene la fórmula (2); (b) la adición de un nucleófilo al producto condensado; y (c) la desprotección del producto de adición, en donde el nucleófilo es el anión litio de dimetilsulfona. Reivindicación 10: Un proceso para la preparación de un compuesto de fórmula (1) o una sal, hidrato, solvato o polimorfo farmacéuticamente aceptable de éste, en donde: R¹ es alquilC₁₋₆; y cada uno de R², R³, R⁴, R⁵ y R⁶ es en cada aparición independientemente hidrógeno, halo, alquilC₁₋₆, alcoxiC₁₋₆, CF₃, -CN o -NO₂, caracterizado porque comprende transformaciones sintéticas seleccionadas del grupo que consiste en: 1) la adición de un auxiliar quiral a una estirilsulfona, en donde el auxiliar quiral es (S)-a-metilbencilamina y la estirilsulfona es de fórmula (3); 2) la transaminación enzimática, en donde el material de partida es de fórmula (4); 3) la reducción diastereoselectiva de borohidruro de un aducto de Ellman, en donde el aducto de Ellman es de fórmula (5), R¹, R², R³, R⁴ y R⁵ son en cada aparición independientemente hidrógeno o alquilC₁₋₆, y el agente de reducción de borohidruro es borohidruro de sodio; 4) la adición estereoselectiva de anión de arilo a aldimina con auxiliar quiral, en donde el anión de arilo es de fórmula (6), la aldimina es de fórmula (7), y el auxiliar quiral es ter-butilsulfinilimina; 5) la epoxidación asimétrica y la apertura de anillo con un nucleófilo de azufre, en donde el material de partida de la epoxidación asimétrica es de fórmula (8), el material de partida de la apertura de anillo es de fórmula (9), y el nucleófilo de azufre es tiometóxido; y sus combinaciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261601226P | 2012-02-21 | 2012-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117963A2 true AR117963A2 (es) | 2021-09-08 |
Family
ID=47755073
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100512A AR090100A1 (es) | 2012-02-21 | 2013-02-19 | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
ARP200100066A AR117963A2 (es) | 2012-02-21 | 2020-01-10 | Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100512A AR090100A1 (es) | 2012-02-21 | 2013-02-19 | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
Country Status (36)
Country | Link |
---|---|
US (3) | US9187417B2 (es) |
EP (4) | EP3312156B1 (es) |
JP (1) | JP2015509496A (es) |
KR (1) | KR101993248B1 (es) |
CN (3) | CN107033042A (es) |
AR (2) | AR090100A1 (es) |
AU (1) | AU2013203283B2 (es) |
BR (3) | BR112014020444B1 (es) |
CA (1) | CA2864517A1 (es) |
CO (1) | CO7061071A2 (es) |
CR (1) | CR20140395A (es) |
CY (2) | CY1121833T1 (es) |
DK (2) | DK3378850T3 (es) |
ES (4) | ES2675168T3 (es) |
HK (1) | HK1205501A1 (es) |
HR (2) | HRP20191249T1 (es) |
HU (2) | HUE048412T2 (es) |
IL (3) | IL234135A (es) |
IN (1) | IN2014DN06740A (es) |
LT (2) | LT3378850T (es) |
MX (2) | MX350731B (es) |
MY (1) | MY168296A (es) |
NI (1) | NI201400093A (es) |
NZ (1) | NZ628028A (es) |
PH (1) | PH12014501865A1 (es) |
PL (2) | PL3312156T3 (es) |
PT (2) | PT3378850T (es) |
RS (2) | RS59071B1 (es) |
RU (1) | RU2632875C2 (es) |
SG (1) | SG11201405035XA (es) |
SI (2) | SI3378850T1 (es) |
TR (1) | TR201910430T4 (es) |
TW (1) | TW201336815A (es) |
UA (1) | UA116773C2 (es) |
WO (1) | WO2013126360A2 (es) |
ZA (1) | ZA201405892B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126906B2 (en) * | 2012-02-21 | 2015-09-08 | Celgene Corporation | Asymmetric synthetic processes for the preparation of aminosulfone compounds |
AR090100A1 (es) | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
WO2014204825A1 (en) | 2013-06-17 | 2014-12-24 | Celgene Corporation | Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
IN2014MU01283A (es) | 2014-04-04 | 2015-10-09 | Cadila Healthcare Ltd | |
US9994522B2 (en) | 2014-05-11 | 2018-06-12 | Mapi Pharma Ltd. | Amorphous form of apremilast |
EP2949645A1 (en) | 2014-05-28 | 2015-12-02 | LEK Pharmaceuticals d.d. | Processes for the preparation of ß-aminosulfone compounds |
CN105622380B (zh) * | 2014-10-29 | 2020-06-30 | 南京安源生物医药科技有限公司 | 一种阿普斯特的制备方法及其中间体 |
CN104447445B (zh) * | 2014-12-05 | 2016-07-06 | 新发药业有限公司 | 一种合成阿普斯特中间体的制备方法 |
CN104744323B (zh) * | 2015-03-11 | 2016-08-31 | 中山奕安泰医药科技有限公司 | 一种阿普斯特手性胺中间体的合成工艺 |
CN104761474B (zh) * | 2015-03-11 | 2016-11-30 | 中山奕安泰医药科技有限公司 | 一种阿普斯特手性胺中间体的合成方法 |
CN104803897A (zh) * | 2015-04-23 | 2015-07-29 | 中山奕安泰医药科技有限公司 | 一种阿普斯特中间体的合成工艺 |
WO2016174685A1 (en) * | 2015-04-27 | 2016-11-03 | Mylan Laboratories Limited | Process for the enantiomeric resolution of apremilast intermediates |
JP2018518489A (ja) * | 2015-06-09 | 2018-07-12 | ドクター レディズ ラボラトリーズ リミテッド | アプレミラスト及びその中間体の調製方法 |
EP3106457A1 (en) | 2015-06-15 | 2016-12-21 | LEK Pharmaceuticals d.d. | A novel synthetic pathway towards apremilast |
EP3144393A1 (en) | 2015-09-18 | 2017-03-22 | LEK Pharmaceuticals d.d. | A synthetic pathway towards apremilast |
EP3356327A1 (en) | 2015-09-29 | 2018-08-08 | Pliva Hrvatska D.O.O. | Processes for the preparation of apremilast and intermediates thereof |
WO2017085568A1 (en) * | 2015-11-19 | 2017-05-26 | Alembic Pharmaceuticals Limited | An improved process and novel polymorphic form of apremilast |
CN105330586B (zh) * | 2015-11-27 | 2017-12-22 | 东华大学 | 一种阿普斯特的制备方法 |
CN105461602B (zh) * | 2015-11-27 | 2018-01-02 | 东华大学 | 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法 |
WO2017094031A2 (en) * | 2015-12-04 | 2017-06-08 | Sun Pharmaceutical Industries Limited | Novel process for preparation of apremilast |
CN106866475B (zh) * | 2015-12-11 | 2018-03-30 | 北大方正集团有限公司 | 一种阿普斯特中间体及其制备方法 |
US10774041B2 (en) | 2016-04-15 | 2020-09-15 | Davuluri Ramamohan Rao | Process for the preparation of apremilast |
US10196355B2 (en) | 2016-06-20 | 2019-02-05 | Johnson Matthey Public Limited Company | Forms of apremilast |
CN106543050B (zh) * | 2016-09-28 | 2018-04-10 | 中南大学湘雅医院 | 一种阿普斯特中间体的合成工艺 |
WO2018061034A1 (en) * | 2016-09-30 | 2018-04-05 | Sun Pharmaceutical Industries Limited | Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine |
WO2018086762A1 (de) | 2016-11-10 | 2018-05-17 | Sms Group Gmbh | VERFAHREN ZUM HERSTELLEN EINES METALLISCHEN BANDES IN EINER GIEßWALZANLAGE |
CN107445875A (zh) * | 2017-03-22 | 2017-12-08 | 陕西科技大学 | 一种用于制备阿普斯特的高纯度中间体的手性拆分方法 |
ES2829253T3 (es) | 2017-04-04 | 2021-05-31 | Quim Sintetica S A | Resolución de compuestos de beta-aminosulfona racémicos |
WO2018184933A1 (en) | 2017-04-04 | 2018-10-11 | Quimica Sintetica, S. A. | Racemic beta-aminosulfone compounds |
CN107827722B (zh) * | 2017-11-23 | 2021-02-19 | 中山奕安泰医药科技有限公司 | 一种3-乙氧基-4-甲氧基苯甲醛的合成方法 |
CN107941945B (zh) * | 2017-11-23 | 2020-12-22 | 中山奕安泰医药科技有限公司 | 一种3-乙氧基-4-甲氧基苯甲腈的检测方法 |
CN107966509B (zh) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法 |
CN107976501B (zh) * | 2017-11-23 | 2020-08-25 | 中山奕安泰医药科技有限公司 | 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法 |
CN108008035B (zh) * | 2017-11-23 | 2020-07-07 | 中山奕安泰医药科技有限公司 | 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法 |
CN108084066A (zh) * | 2017-12-12 | 2018-05-29 | 中山大学 | 一种阿普斯特及对映异构体的合成方法 |
JP6673614B1 (ja) * | 2018-10-16 | 2020-03-25 | 東芝エレベータ株式会社 | 防音装置 |
CN113896674B (zh) * | 2021-09-01 | 2023-10-27 | 深圳华中科技大学研究院 | 一种阿普斯特的合成方法 |
WO2023116707A1 (zh) | 2021-12-21 | 2023-06-29 | 赣州和美药业有限公司 | 噻吩衍生物的制备 |
CN115850129B (zh) * | 2023-02-28 | 2023-05-16 | 凯莱英生命科学技术(天津)有限公司 | (s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙胺的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3878252A (en) * | 1970-09-24 | 1975-04-15 | Burroughs Wellcome Co | Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide |
GB1261455A (en) * | 1969-03-06 | 1972-01-26 | Burroughs Wellcome Co | Improvements in or relating to substituted acrylonitriles |
DE2051871A1 (en) * | 1969-05-16 | 1971-11-18 | The Wellcome Foundation Ltd., London | Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents |
EE9800299A (et) | 1996-03-22 | 1999-06-15 | The Du Pont Merck Pharmaceutical Company | R-a-propüül-piperonüülamiini ja selle analoogide uudne asümmeetriline sünteesimine |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
DE60330187D1 (de) | 2002-12-30 | 2009-12-31 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
US7208526B2 (en) | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
AU2009206368B2 (en) * | 2008-01-25 | 2014-12-11 | Vtv Therapeutics Llc | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors |
US8242310B2 (en) | 2008-09-10 | 2012-08-14 | Celgene Corporation | Processes for the preparation of aminosulfone compounds |
ME01883B (me) * | 2009-06-18 | 2014-12-20 | Concert Pharmaceuticals Inc | Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa |
CN102639498A (zh) | 2009-10-09 | 2012-08-15 | 细胞基因公司 | 制备2-(1-苯乙基)异吲哚啉-1-酮化合物的方法 |
WO2012097116A2 (en) | 2011-01-14 | 2012-07-19 | Celgene Corporation | Isotopologues of isoindole derivatives |
AR090100A1 (es) * | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
US9126906B2 (en) * | 2012-02-21 | 2015-09-08 | Celgene Corporation | Asymmetric synthetic processes for the preparation of aminosulfone compounds |
-
2013
- 2013-02-19 AR ARP130100512A patent/AR090100A1/es active IP Right Grant
- 2013-02-20 TW TW102105901A patent/TW201336815A/zh unknown
- 2013-02-20 KR KR1020147026186A patent/KR101993248B1/ko active IP Right Grant
- 2013-02-20 EP EP17197504.8A patent/EP3312156B1/en active Active
- 2013-02-20 UA UAA201410289A patent/UA116773C2/uk unknown
- 2013-02-20 BR BR112014020444-6A patent/BR112014020444B1/pt active IP Right Grant
- 2013-02-20 TR TR2019/10430T patent/TR201910430T4/tr unknown
- 2013-02-20 MX MX2016016157A patent/MX350731B/es unknown
- 2013-02-20 NZ NZ628028A patent/NZ628028A/en unknown
- 2013-02-20 SG SG11201405035XA patent/SG11201405035XA/en unknown
- 2013-02-20 CN CN201710255841.0A patent/CN107033042A/zh active Pending
- 2013-02-20 JP JP2014558783A patent/JP2015509496A/ja active Pending
- 2013-02-20 CN CN201380020005.4A patent/CN104245668B/zh active Active
- 2013-02-20 LT LTEP18168969.6T patent/LT3378850T/lt unknown
- 2013-02-20 AU AU2013203283A patent/AU2013203283B2/en active Active
- 2013-02-20 WO PCT/US2013/026780 patent/WO2013126360A2/en active Application Filing
- 2013-02-20 EP EP20150560.9A patent/EP3702347B1/en active Active
- 2013-02-20 ES ES13706898.7T patent/ES2675168T3/es active Active
- 2013-02-20 HU HUE18168969A patent/HUE048412T2/hu unknown
- 2013-02-20 RU RU2014138037A patent/RU2632875C2/ru active
- 2013-02-20 RS RS20190895A patent/RS59071B1/sr unknown
- 2013-02-20 BR BR122021020040-8A patent/BR122021020040B1/pt active IP Right Grant
- 2013-02-20 BR BR122021020046-7A patent/BR122021020046B1/pt active IP Right Grant
- 2013-02-20 EP EP18168969.6A patent/EP3378850B8/en active Active
- 2013-02-20 PL PL17197504T patent/PL3312156T3/pl unknown
- 2013-02-20 EP EP13706898.7A patent/EP2817288B1/en active Active
- 2013-02-20 LT LTEP17197504.8T patent/LT3312156T/lt unknown
- 2013-02-20 ES ES17197504T patent/ES2735801T3/es active Active
- 2013-02-20 CA CA2864517A patent/CA2864517A1/en not_active Withdrawn
- 2013-02-20 MX MX2014010002A patent/MX344190B/es active IP Right Grant
- 2013-02-20 ES ES18168969T patent/ES2773686T3/es active Active
- 2013-02-20 PT PT181689696T patent/PT3378850T/pt unknown
- 2013-02-20 ES ES20150560T patent/ES2971710T3/es active Active
- 2013-02-20 PT PT17197504T patent/PT3312156T/pt unknown
- 2013-02-20 US US13/771,164 patent/US9187417B2/en active Active
- 2013-02-20 HU HUE17197504 patent/HUE044192T2/hu unknown
- 2013-02-20 SI SI201331685T patent/SI3378850T1/sl unknown
- 2013-02-20 SI SI201331526T patent/SI3312156T1/sl unknown
- 2013-02-20 CN CN202110092737.0A patent/CN112812044B/zh active Active
- 2013-02-20 RS RS20200185A patent/RS60036B1/sr unknown
- 2013-02-20 DK DK18168969.6T patent/DK3378850T3/da active
- 2013-02-20 MY MYPI2014702288A patent/MY168296A/en unknown
- 2013-02-20 PL PL18168969T patent/PL3378850T3/pl unknown
- 2013-02-20 IN IN6740DEN2014 patent/IN2014DN06740A/en unknown
- 2013-02-20 DK DK17197504.8T patent/DK3312156T3/da active
-
2014
- 2014-08-12 ZA ZA2014/05892A patent/ZA201405892B/en unknown
- 2014-08-14 IL IL234135A patent/IL234135A/en active IP Right Grant
- 2014-08-18 PH PH12014501865A patent/PH12014501865A1/en unknown
- 2014-08-20 NI NI201400093A patent/NI201400093A/es unknown
- 2014-08-21 CO CO14183628A patent/CO7061071A2/es unknown
- 2014-08-21 CR CR20140395A patent/CR20140395A/es unknown
-
2015
- 2015-06-25 HK HK15106059.8A patent/HK1205501A1/xx unknown
- 2015-10-14 US US14/882,564 patent/US9586897B2/en active Active
-
2017
- 2017-01-25 US US15/414,782 patent/US9688623B2/en active Active
- 2017-05-23 IL IL252459A patent/IL252459B/en active IP Right Grant
-
2019
- 2019-07-11 CY CY20191100742T patent/CY1121833T1/el unknown
- 2019-07-12 HR HRP20191249TT patent/HRP20191249T1/hr unknown
-
2020
- 2020-01-10 AR ARP200100066A patent/AR117963A2/es unknown
- 2020-02-13 HR HRP20200245TT patent/HRP20200245T1/hr unknown
- 2020-02-21 CY CY20201100163T patent/CY1122799T1/el unknown
- 2020-03-04 IL IL273050A patent/IL273050A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117963A2 (es) | Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina | |
MX2019002769A (es) | Metodos de preparacion de un catalizador. | |
AR085155A1 (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos | |
MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
BR112014010401A8 (pt) | Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
AR090566A1 (es) | Proceso para la produccion de inhibidores de crr | |
AR105494A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
AR098871A1 (es) | Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa | |
TN2018000393A1 (en) | Pegylated carfilzomib compounds | |
AR098522A1 (es) | Compuesto de triazolo-piridina | |
PH12016500963A1 (en) | Novel dgat2 inhibitors | |
BR112015015368A2 (pt) | composições de absorventes de dejetos de animais revestidas debaixa densidade | |
BR112018073490A2 (pt) | 6.7.beta-epóxidos esteroides como intermediários químicos | |
MX2018014164A (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico. | |
WO2016089758A3 (en) | Organo-1-oxa-4-azonium cyclohexane compounds | |
MX2012013610A (es) | Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina. | |
PH12014501712A1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
MY191081A (en) | Compound targetting il-23a and b-cell activating factor (baff) and uses thereof | |
BR112015009567A2 (pt) | compostos de benzil sulfonamida novos úteis como inibidores de mogat-2 | |
AR102088A1 (es) | Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina | |
BR112016026310A2 (pt) | processo para a reação de compostos químicos | |
MX2021005343A (es) | Proceso para la preparacion de isoxazolinas opticamente enriquecidas. | |
AR100095A1 (es) | Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico | |
BR112017003121A2 (pt) | método para a síntese de um óxido de fosfina de hidrogênio heterocíclico |